iPhone app iPad app Android phone app Android tablet app

Institutional Review Board

There Has to Be a Better Way

Jonathan Agin | Posted 01.28.2013 | Impact
Read More: Clinical Trials, Big Pharma, Pharmaceutical Industry, Children, Memorial Sloan-Kettering Cancer Center, Cancer Research, Institutional-Review-Board, Cancer, Federal Drug Administration, Health Care, Children's Health, Childhood Cancer, Parents, Impact News
Jonathan Agin

I am convinced that one of the biggest impediments to finding cures for childhood cancer is the way we force our kids to fight. The regulatory and institutional red tape cause many parents not to enroll their children in clinical trials.

Read Whole Story

Cancer One, War Less Than One

Jonathan Agin | Posted 03.21.2012 | Impact
Read More: Clinical Trials, Cancer, War on Cancer, Fda, Memorial Sloan-Kettering Cancer Center, Alexis Agin, Institutional-Review-Board, Childhood Cancer, Impact News
Jonathan Agin

The FDA and the institutional review boards, rather than being impediments to patients gaining access to potentially life-saving drugs, must become a partner with patients. Regulatory impediments before parents must be eased.

Read Whole Story